01—Abstract
Summary
Summary of the 8-K filed May 10, 2024. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. (EXEL) filed a Form 8-K on May 10, 2024 under Item 8.01 (Other Events) to disclose patent litigation related to CABOMETYX (cabozantinib) tablets.
On March 27, 2024, the company received notice from Cipla Ltd. and Cipla USA, Inc. that Cipla had amended its Abbreviated New Drug Application (ANDA), originally filed with the FDA more than one year earlier, to add Paragraph IV certifications. The amended ANDA seeks approval to market generic CABOMETYX in 20 mg and 40 mg strengths, in addition to the 60 mg strength in the original application, before the expiration of seven listed U.S. patents. On May 9, 2024, Exelixis filed a patent infringement complaint in the U.S. District Court for the District of Delaware against Cipla.
The complaint asserts five of the patents (Nos. 8,877,776, 11,091,439, 11,091,440, 11,098,015 and 11,298,349) arising from the amended ANDA filing. Among other relief, Exelixis seeks an order that any FDA approval of Cipla's ANDA take effect no earlier than the expiration of all five asserted patents, the latest of which expires on February 10, 2032, along with equitable relief enjoining Cipla from infringing these patents.
For investors, the filing signals that Exelixis is actively defending CABOMETYX's patent protection against a generic challenger. The filing does not state the financial impact of the litigation or the outcome of any proceeding, and it describes only the legal actions and the relief sought.
02—Key points
Key Highlights
- Cipla Ltd. and Cipla USA, Inc. amended their ANDA on or before March 27, 2024 to add Paragraph IV certifications covering CABOMETYX 20 mg, 40 mg and 60 mg tablets.
- The amended ANDA challenges seven U.S. patents: Nos. 8,877,776, 9,724,342, 10,039,757, 11,091,439, 11,091,440, 11,098,015 and 11,298,349.
- On May 9, 2024, Exelixis filed a patent infringement complaint against Cipla in the U.S. District Court for the District of Delaware.
- The complaint asserts five patents: Nos. 8,877,776, 11,091,439, 11,091,440, 11,098,015 and 11,298,349.
- Exelixis seeks an order that FDA approval of Cipla's ANDA take effect no earlier than expiration of the asserted patents, the latest of which expires February 10, 2032.
- Exelixis also seeks equitable relief enjoining Cipla from infringing the asserted patents.
- The filing discloses no financial impact or litigation outcome.
03—Questions
Frequently Asked Questions
What product is at the center of this patent dispute?
The dispute concerns CABOMETYX tablets, which Cipla seeks to market in generic form at 20 mg, 40 mg and 60 mg dosage strengths.
What did Cipla do that triggered the lawsuit?
Cipla amended its ANDA, originally filed with the FDA more than one year earlier, to assert additional Paragraph IV certifications covering the 20 mg and 40 mg strengths in addition to the 60 mg strength in the original application.
Which patents does Exelixis assert in the complaint?
Exelixis asserts U.S. Patents No. 8,877,776, 11,091,439, 11,091,440, 11,098,015 and 11,298,349 arising from Cipla's amended ANDA filing.
When does the latest asserted patent expire?
The filing states that the latest of the asserted patents expires on February 10, 2032.
What relief is Exelixis seeking?
Exelixis seeks, among other relief, an order that the effective date of any FDA approval of Cipla's ANDA be no earlier than expiration of the asserted patents, and equitable relief enjoining Cipla from infringing them.
04—Continue